Bridgeway Capital Management’s Ovid Therapeutics OVID Stock Holding History

Bridgeway Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$212K	Hold	95,434	–	–	﹤0.01%	1024
2025 Q4	$156K	Hold	95,434	–	–	﹤0.01%	1059
2025 Q3	$124K	Hold	95,434	–	–	﹤0.01%	1081
2025 Q2	$31.5K	Hold	95,434	–	–	﹤0.01%	1151
2025 Q1	$29.8K	Sell	95,434 -133,681	-58%	-$82.2K	﹤0.01%	1144
2024 Q4	$214K	Sell	229,115 -80,425	-26%	-$90K	﹤0.01%	993
2024 Q3	$365K	Sell	309,540 -42,630	-12%	-$44.5K	0.01%	931
2024 Q2	$271K	Sell	352,170 -5,700	-2%	-$15.9K	0.01%	988
2024 Q1	$1.09M	Sell	357,870 -81,475	-19%	-$273K	0.02%	729
2023 Q4	$1.41M	Sell	439,345 -19,355	-4%	-$66.2K	0.03%	681
2023 Q3	$1.76M	Sell	458,700 -342,452	-43%	-$1.23M	0.04%	582
2023 Q2	$2.63M	Sell	801,152 -26,428	-3%	-$89.7K	0.06%	468
2023 Q1	$2.14M	Sell	827,580 -83,620	-9%	-$198K	0.06%	505
2022 Q4	$1.69M	Buy	911,200 +2,700	+0.3%	+$4.6K	0.04%	602
2022 Q3	$1.67M	Sell	908,500 -75,200	-8%	-$157K	0.04%	582
2022 Q2	$2.12M	Buy	983,700 +615,600	+167%	+$1.49M	0.05%	522
2022 Q1	$1.16M	Buy	368,100 +156,700	+74%	+$493K	0.02%	743
2021 Q4	$679K	Hold	211,400	–	–	0.01%	893
2021 Q3	$710K	Hold	211,400	–	–	0.01%	932
2021 Q2	$827K	Sell	211,400 -18,000	-8%	-$71K	0.01%	921
2021 Q1	$922K	Buy	+229,400	New	+$762K	0.02%	890
2020 Q2	–	Sell	-242,600	Closed	-$723K	–	1377
2020 Q1	$723K	Hold	242,600	–	–	0.02%	651
2019 Q4	$1.01M	Buy	242,600 +32,400	+15%	+$102K	0.01%	737
2019 Q3	$681K	Buy	210,200 +150,000	+249%	+$341K	0.01%	841
2019 Q2	$111K	Sell	60,200 -24,240	-29%	-$43.3K	﹤0.01%	1241
2019 Q1	$149K	Sell	84,440 -14,000	-14%	-$35K	﹤0.01%	1252
2018 Q4	$238K	Sell	98,440 -10,000	-9%	-$45.6K	﹤0.01%	1187
2018 Q3	$615K	Hold	108,440	–	–	0.01%	1089
2018 Q2	$846K	Hold	108,440	–	–	0.01%	933
2018 Q1	$767K	Buy	108,440 +59,440	+121%	+$481K	0.01%	933
2017 Q4	$484K	Buy	+49,000	New	+$450K	0.01%	1099

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bridgeway Capital Management's OVID Position: Q1 2026 in Review

Bridgeway Capital Management held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 95,434 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Bridgeway Capital Management first reported a position in OVID in Q4 2017 and has held it in 31 quarters since. The position peaked at $2.63M in Q2 2023. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Bridgeway Capital Management held 95,434 shares of Ovid Therapeutics worth $212K as of Q1 2026.
Bridgeway Capital Management left its Ovid Therapeutics share count unchanged in Q1 2026.
Ovid Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1024 holding.
Bridgeway Capital Management first reported a position in Ovid Therapeutics in Q4 2017 and has held it in 31 quarters since.
Bridgeway Capital Management's Ovid Therapeutics position peaked at $2.63M in Q2 2023.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.